Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 17 Jun 2025 |
| U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer | 3 Jun 2025 |
| Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market | 23 May 2025 |
| Orion to host Capital Markets Day today, 22 May 2025, in Helsinki | 22 May 2025 |
| Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers | 21 May 2025 |